"Aminoisobutyric Acids" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A group of compounds that are derivatives of the amino acid 2-amino-2-methylpropanoic acid.
| Descriptor ID |
D000621
|
| MeSH Number(s) |
D02.241.081.114.968.249 D12.125.070.075 D12.125.190.055
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Aminoisobutyric Acids".
Below are MeSH descriptors whose meaning is more specific than "Aminoisobutyric Acids".
This graph shows the total number of publications written about "Aminoisobutyric Acids" by people in this website by year, and whether "Aminoisobutyric Acids" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2015 | 0 | 1 | 1 |
| 2016 | 1 | 0 | 1 |
| 2017 | 0 | 3 | 3 |
| 2018 | 0 | 8 | 8 |
| 2019 | 0 | 1 | 1 |
| 2020 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Aminoisobutyric Acids" by people in Profiles.
-
Rational approach toward COVID-19 main protease inhibitors via molecular docking, molecular dynamics simulation and free energy calculation. Sci Rep. 2020 10 19; 10(1):17716.
-
Glecaprevir and Maraviroc are high-affinity inhibitors of SARS-CoV-2 main protease: possible implication in COVID-19 therapy. Biosci Rep. 2020 06 26; 40(6).
-
Evolutionary Pathways to Persistence of Highly Fit and Resistant Hepatitis C Virus Protease Inhibitor Escape Variants. Hepatology. 2019 09; 70(3):771-787.
-
APASL clinical practice recommendation: how to treat HCV-infected patients with renal impairment? Hepatol Int. 2019 Mar; 13(2):103-109.
-
Direct-acting antivirals for chronic hepatitis C virus genotype 5 and 6 infections. Lancet Gastroenterol Hepatol. 2019 01; 4(1):5-6.
-
Glecaprevir/pibrentasvir in patients with chronic HCV and recent drug use: An integrated analysis of 7 phase III studies. Drug Alcohol Depend. 2019 01 01; 194:487-494.
-
Treatment of hepatitis C virus genotype 4 in the DAA era. Virol J. 2018 11 22; 15(1):180.
-
Glecaprevir/Pibrentasvir Treatment in Liver or Kidney Transplant Patients With Hepatitis C Virus Infection. Hepatology. 2018 10; 68(4):1298-1307.
-
Deferred treatment with sofosbuvir-velpatasvir-voxilaprevir for patients with chronic hepatitis C virus who were previously treated with an NS5A inhibitor: an open-label substudy of POLARIS-1. Lancet Gastroenterol Hepatol. 2018 08; 3(8):559-565.
-
Glecaprevir-Pibrentasvir for 8 or 12 Weeks in HCV Genotype 1 or 3 Infection. N Engl J Med. 2018 01 25; 378(4):354-369.